CURRICULUM VITAE

 
NAME                                 Yanshuo Cao （曹彦硕）
CURRENT POSITION
Dec. 2015-present    Medical Oncology Staff
                   Peking University Cancer Hospital, China
EDUCATION
Sep. 2003-Jul. 2011         Doctor of Medicine (MD)
Peking University, Beijing, China
PROFESSIONAL DEVELOPMENT
Apr. 2009-Nov. 2009  Internship (internal medicine)
Peking University Third Hospital, Beijing, China
Dec. 2009-Apr. 2011  Internship (medical oncology)
Beijing Cancer Hospital & Institute, Beijing, China
Aug. 2011-Jun. 2012  Residency Training (medical oncology)
Beijing Cancer Hospital & Institute, Beijing, China
Jun. 2012-Oct. 2012        Residency Training (internal medicine)
Peking University First Hospital, Beijing, China
Oct. 2012-Nov. 2015  Residency Training (medical oncology)
Beijing Cancer Hospital & Institute, Beijing, China
Dec. 2015-Jun. 2016        Fellowship Training (GI medical oncology)
Beijing Cancer Hospital & Institute, Beijing, China
May. 2017-Jul. 2017        Summer Program in Clinical Epidemiology and Biostatistics
                   University Health Network, Toronto, Canada
Jul. 2017-Aug. 2017   ASCO/AACR Methods in Clinical Cancer Research Workshop
                   Vail, United States, 2017
Jul. 2016 -Jun. 2018        Clinical Fellow
Division of Medical Oncology and Hematology, Princess Margaret Cancer Center,  
Faculty of Medicine, University of Toronto, Toronto, Canada
MEDICAL LICENSE INFORMATION
       Certificate of Qualification for Medical Doctor (Clinical Medicine)

• Date of Issue: Dec. 15, 2010
• Certificate Serial No.: 201011110110107198501172428
• Issuing Agency: Beijing Health Bureau and the Ministry of Health of the People's Republic of China

CLINICAL RESEARCH EXPERIENCES
    Sub-investigator. A double-blind, placebo-controlled, randomized, multicenter Phase III Study evaluating the efficacy and safety of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction and gastric cancer.
    Sub-investigator. Randomized, double-blind, Phase III Study of TAS-102 versus placebo in Asian patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
    Sub-investigator. Randomized, open, multi-center Study of S-1+oxaliplatin versus S-1+ cisplatin in patients with metastatic, diffuse-type gastric adenocarcinoma.
    Sub-investigator. A phase II, multi-center Study to evaluate the safety and efficacy of ABI-007 plus gemcitabine in Chinese patients with metastatic pancreatic adenocarcinoma.
ACADEMIC ACTIVITIES
    Member of American Society of Clinical Oncology (ASCO)
    Member of American Association for Cancer Research (AACR)
    Member of European Society for Medical Oncology (ESMO)
    Member of Chinese Society of Clinical Oncology (CSCO)
    Member of Chinese Gastrointestinal Oncology Group (CGOG)
    Assist in organizing the 1^st, 3^rd, 4^th and 5^th CGOG meeting, 2010-2015
    Editorial Assistant of Annals of Oncology Excerpts China Edition, 2012-2014
    Core Member of International Information Exchange Group of CSCO, 2015-present
   Assist in organizing the 12^th International Gastric Cancer Congress scheduled for Beijing, 2017
PUBLICATIONS
     Cao Y, Zhang X, Li J, Gong J, Lu M, Lu Z, Wang X, Zhou J, Li J, Li Y, Shen L. Management of gastric cancer patients with ovarian metastasis: a retrospective study. Journal of Multidisciplinary Cancer Management (Electronic Version). 2018, vol.4, No.1, 54-6.
     Cao Y, Sun L, Shen L. Next-generation sequencing assistants in diagnosis of testicular metastatic adenocarcinoma after gastric cancer surgery. Chinese Journal of Practical Surgery. 2015, vol.35, No.9, 970-3.
     Li Y, Gong J, Zhang Q, Lu Z, Gao J, Cao Y, Shen L. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer. 2016, vol 114, 138-45.
    Zhang X, Wu y, Gong J, Lu Z, Zhou J, Wang X, Lu M, Li J, Cao Y, Li Y, Li J, Shen L. Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma. Zhonghua Zhong Liu Za Zhi. 2014, vol 36, No. 3, 223-7.
    Li Y, Zhang X, Ge S, Gao J, Gong J, Lu M, Zhang Q, Cao Y, Wang D, Lin P, Shen L. Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer. Oncotarget. 2014, vol.5, No.16, 6594-602.
ONGOING RESEARCH PROJECTS
    Tumor platinum concentrations and pathological responses following cisplatin-containing chemotherapy in gastric cancer patients; Supervisor: Dr. Eric Chen (manuscript under review)
  Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various degrees of renal dysfunction (RD); Supervisor: Dr. Eric Chen (abstract presented at ASCO 2018, Merit Award)
  The clinicopathological characters and prognostic factors of young female gastric cancer patients; Supervisor: Dr. Lin Shen (Abstract presented at ASCO GI Symposium 2018)
 Platinum deposition in skin as a possible mechanism for peripheral sensory neuropathy (PSN) in patients (pts) with colorectal cancer (CRC) following oxaliplatin-based therapy; Supervisor: Dr. Eric Chen (Abstract presented at ASCO GI Symposium 2018)
    Retrospective review of safety and efficacy of sorafenib in patients with recurrent hepatocellular carcinoma post liver transplantation. (co-investigator); Supervisor: Dr. Eric Chen (Abstract presented at ASCO GI Symposium 2017)
    Tumoural platinum concentration as a predictor for survival in patients with gastric or gastroesophageal junction cancer following perioperative chemotherapy; Supervisor: Dr. Eric Chen (Project submitted for CIHR Annual Grant competition 2018)
    A Randomized, Phase II Study of Gemcitabine/Cisplatin versus Epirubicin, Cisplatin plus Capecitabine in EBV-associated Metastatic/unresectable Gastric Cancer; Supervisor: Dr. Eric Chen (Project submitted for CIHR Annual Grant competition 2018)